In a groundbreaking advancement for public health, the World Health Organization (WHO) has approved the first malaria treatment specifically designed for infants, known as Coartem Baby. This development promises to significantly reduce the mortality rate among newborns afflicted with malaria, particularly in regions where the disease remains endemic, such as sub-Saharan Africa.
Addressing a Critical Gap in Treatment
Malaria continues to pose a severe health threat, particularly to young children. In many parts of Africa, an alarming 18% of infants under six months are infected with the disease. Tragically, malaria claimed the lives of approximately 610,000 individuals in 2024, with a disproportionate number—around 75%—comprising children under five. Historically, infants have been treated with medications formulated for older children, which increases the potential for dosing errors and adverse side effects.
Dr. Tedros Adhanom Ghebreyesus, the WHO’s Director-General, emphasised the importance of this milestone, stating, “For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities. But today, the story is changing.” The introduction of Coartem Baby, which is formulated as cherry-flavoured tablets that can dissolve in liquids, including breast milk, represents a pivotal shift in how this vulnerable population can be treated.
The Science Behind Coartem Baby
Coartem Baby contains two antimalarial compounds—artemether and lumefantrine—developed collaboratively by the multinational pharmaceutical firm Novartis and the Medicines for Malaria Venture (MMV). This formulation is particularly significant as it addresses the misconception that infants are immune to malaria due to maternal antibodies received during pregnancy and breastfeeding. Recent research has indicated that this is not the case, leading to a pressing need for treatments that cater specifically to newborns and young infants.
Dr. Martin Fitchet, CEO of MMV, remarked on the historic nature of the WHO’s approval, stating, “For too long, newborns and young infants with malaria have fallen through the cracks because existing treatments were not designed with them in mind.” The drug has already been launched in Ghana, where it is being administered to infants like Baby Wonder, who was treated successfully after being diagnosed with malaria at just 12 weeks old.
Real-World Impact and Future Prospects
The introduction of Coartem Baby has already shown promising results in clinical settings. In Ghana, Baby Wonder’s mother, Naomi, described her fears when her son contracted malaria, particularly given his underweight status at birth. Thanks to the timely intervention of healthcare providers, Baby Wonder received the new treatment and is now healthy and thriving. Dr. Emmanuel Aidoo, a paediatrician at Methodist Hospital in Ankaase, noted the significant change this treatment brings to the healthcare landscape: “Having a new treatment tailor-made for infants that is well tolerated gives us confidence.”
Novartis has committed to providing Coartem Baby on a largely not-for-profit basis in malaria-affected regions, which will facilitate broader accessibility. The backing of philanthropic organisations, including the Gates Foundation, further strengthens the initiative, ensuring that financial constraints do not hinder the fight against malaria in vulnerable populations.
Why it Matters
The approval of Coartem Baby marks a significant turning point in the global battle against malaria, particularly for the youngest and most vulnerable demographic. By providing a safe and effective treatment option for infants, health authorities can drastically reduce the mortality rates associated with this preventable disease. This advancement not only saves lives but also fosters hope for communities that have long endured the devastating impacts of malaria. As we continue to combat this disease, the prioritisation of tailored treatments for all age groups will be crucial in achieving long-term public health goals.